Medical devices industry venture financing deals in June 2020 total $645.48m in US

22 July 2020 (Last Updated July 22nd, 2020 17:39)

Medical devices industry venture financing deals in June 2020 total $645.48m in US

Total medical devices industry venture financing deals in June 2020 worth $645.48m were announced in the US, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 51.7% over the previous month and a drop of 5% when compared with the last 12-month average of $679.47m.

The US held a 64.2% share of the global medical devices industry venture financing deal value that totalled $1.01bn in June 2020.

In terms of deal activity, the US recorded 41 deals during June 2020, marking a decrease of 29.3% over the previous month and a drop of 31.7% over the 12-month average.

The US medical devices industry venture financing deals in June 2020: Top deals

The top five medical devices industry venture financing deals accounted for 47.6% of the overall value during June 2020.

The combined value of the top five medical devices venture financing deals stood at $307.3m, against the overall value of $645.48m recorded for the month.

The top five medical devices industry deals of June 2020 tracked by GlobalData were:

1) ACME Capital, Decheng Capital, Foresite Capital Management, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners’ $100m venture financing of Cue Health

2) The $64m venture financing of Somatus by Blue Venture Fund, Deerfield ManagementLP, Flare Capital Partners, Longitude Capital Management Co, Optum Ventures and Town Hall Ventures

3) Abbott Laboratories, Cormorant Asset Management, Janus Henderson Investors, Quadrant Capital Advisors, Senvest Capital and Smile Group’s $55m venture financing of Bigfoot Biomedical

4) The $44.4m venture financing of Infinity BiologiX by Viking Global Investors

5) ATON Partners and The Perceptive Xontogeny Venture Fund’s venture financing of CereVasc for $43.9m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.